Logos Global Management LP Neurocrine Biosciences Inc Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $14.1 Million - $17.6 Million	-150,000 Reduced 50.0%	150,000 $16.9 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $8.95 Million - $10.5 Million	100,000 Added 50.0%	300,000 $28.3 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $18.8 Million - $24.6 Million	200,000 New	200,000 $20.2 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $13.3 Million - $17.5 Million	-175,000 Reduced 36.84%	300,000 $29.2 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $34.4 Million - $45 Million	475,000 New	475,000 $44.5 Million

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.